Charles Darwin University

CDU eSpace
Institutional Repository

CDU Staff and Student only

Emerging drugs for bronchiectasis: An update

Chang, Anne B., Marsh, Robyn L., Smith-Vaughan, Heidi C. and Hoffman, Lucas (2015). Emerging drugs for bronchiectasis: An update. Expert Opinion on Emerging Drugs,20(2):277-297.

Document type: Journal Article
Citation counts: Altmetric Score Altmetric Score is 1
Google Scholar Search Google Scholar

IRMA ID 11381xPUB116
Title Emerging drugs for bronchiectasis: An update
Author Chang, Anne B.
Marsh, Robyn L.
Smith-Vaughan, Heidi C.
Hoffman, Lucas
Journal Name Expert Opinion on Emerging Drugs
Publication Date 2015
Volume Number 20
Issue Number 2
ISSN 1472-8214   (check CDU catalogue open catalogue search in new window)
Scopus ID 2-s2.0-84930018062
Start Page 277
End Page 297
Total Pages 21
Place of Publication United Kingdom
Publisher Taylor & Francis
HERDC Category C1 - Journal Article (DIISR)
Abstract Introduction: Recent research has confirmed the increasing burden of bronchiectasis, in affluent and developing countries. Bronchiectasis, the destruction and dilation of airways, is due to a variety of causes and is characterised by a self-perpetuating cycle of airway inflammation, infection and obstruction that results in substantial morbidity and mortality. Improved therapies that address these three components, and the diseases that both cause and result from bronchiectasis are required.

Areas covered: In this review, we update our previous summary of the clinical features, pathophysiology and epidemiology of bronchiectasis among adults and children, highlighting the most recent advances in therapeutics. We discuss current treatment strategies and then identify key goals for future research on the causes and treatments of a variety of types of bronchiectasis.

Expert opinion: Bronchiectasis remains an orphan disease with respect to the development of new therapies. There has been progress in the recognition and studies but further research is now required on the pathogenesis, prevention, and treatment of bronchiectasis in order to decrease its high burden. Such advances will require a concerted, global effort to coordinate studies of both the pathophysiology and potential treatments of this heterogeneous, chronic disease that affects people of all ages and demographics.
Keywords adults
DOI   (check subscription with CDU E-Gateway service for CDU Staff and Students  check subscription with CDU E-Gateway in new window)
Version Filter Type
Access Statistics: 184 Abstract Views  -  Detailed Statistics
Created: Tue, 26 Jul 2016, 12:43:57 CST